40130-97-0Relevant articles and documents
NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS
-
Paragraph 0229, (2019/01/21)
The present invention discloses compounds according to Formula (I) Wherein R1, R2, L, A1, A2, A3, Cy and the subscript n are as defined herein. The present invention relates to antagonists compounds of sphingosine 1-phosphate (SIP) receptor, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, inflammatory diseases, respiratory diseases, autoimmune diseases, metabolic diseases, cardiovascular diseases, and/or proliferative diseases by administering the compound of the invention.
Melatonin derivatives - I - Synthesis of N-succinyl-6-chloro-5-methoxytryptamine
Batandier,Marsura,Luu-Duc
, p. 227 - 230 (2007/10/02)
-
Synthesis and evaluation of the antiovulatory activity of a variety of melatonin analogues
Flaugh,Crowell,Clemens,Sawyer
, p. 63 - 69 (2007/10/04)
A series of melatonin analogues was synthesized and examined for ovulation-blocking activity. Deviation from the 5-methoxy group or substitution of the 1 position prevented activity. Activity was not particularly sensitive to minor variations in the N-acyl group nor was it significantly altered by methylation of position 2 or the α-methylene; however, a pronounced enhancement resulted from halogenation of the 6 position.